Janus Henderson Group
CTMX icon

Janus Henderson Group’s CytomX Therapeutics CTMX Stock Holding History

Janus Henderson Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$220K Buy
+46,700
New +$237K ﹤0.01% 2308
2024
Q4 		– Sell
-4,809,518
Closed -$5.7M – 2537
2024
Q3 		$5.7M Sell
4,809,518
-1,492,465
-24% -$1.9M ﹤0.01% 846
2024
Q2 		$7.72M Buy
+6,301,983
New +$12.5M ﹤0.01% 723
2021
Q2 		– Sell
-312,667
Closed -$2.42M – 1622
2021
Q1 		$2.42M Buy
+312,667
New +$2.47M ﹤0.01% 1147

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group's CTMX Position: Q1 2026 in Review

Janus Henderson Group opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 46,700 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in CTMX as recently as Q3 2024.

Janus Henderson Group first reported a position in CTMX in Q1 2021 and has held it in 4 quarters since. The position peaked at $7.72M in Q2 2024. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Janus Henderson Group held 46,700 shares of CytomX Therapeutics worth $220K as of Q1 2026.
  • CytomX Therapeutics was a new Janus Henderson Group position in Q1 2026.
  • CytomX Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2308 holding.
  • Janus Henderson Group first reported a position in CytomX Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Janus Henderson Group's CytomX Therapeutics position peaked at $7.72M in Q2 2024.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.